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Abstract 
 
With the aim of improving viral distribution and tumor penetration, we have 
engineered decorin expressing replication-incompetent (dl-LacZ-DCNG) and -
competent (Ad-ΔE1B-DCNG) adenoviruses. In both tumor spheroids and established 
solid tumors in vivo, administration of dl-LacZ-DCNG resulted in greater transduction 
efficiency and viral spread throughout the tumor mass. Ad-ΔE1B-DCNG also enhanced 
viral distribution and tumor spread, leading to an increased anti-tumor effect and 
survival advantage. Upon histological analysis, Ad-ΔE1B-DCNG also elicited greater 
percentage of apoptotic cells and extensive necrosis compared to those from untreated 
or control virus-treated tumors. Furthermore, Ad-ΔE1B-DCNG substantially decreased 
extracellular matrix components within the tumor tissue, while normal tissue adjacent to 
the tumor was not affected. Finally, intratumoral administration of Ad-ΔE1B-DCNG did 
not enhance but inhibited the formation of pulmonary metastases of B16BL6 melanoma 
cells in mice. Taken together, these data demonstrate the utility of decorin as a 
dispersion agent and suggest its utility and potential in improving the efficacy of 
replicating adenovirus-mediated cancer gene therapy. 
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Introduction 
 
Adenoviral vectors’ inefficient ability to disseminate throughout tumor tissues 
remains a major obstacle in the development of a successful cancer gene therapy 1-6.  
Number of groups is seeking to address this problem by using oncolytic adenoviruses 
that selectively replicate in tumor cells. Bischoff and coworkers reported that by 
deleting an adenovirus early gene, E1B 55kDa, Ad selectively proliferated in cancer 
cells 7. Subsequently in our previous report, we have shown that E1B 19kDa- and E1B 
55kDa-double deleted replication-competent adenovirus, Ad-ΔElB19/55 (referred to as 
Ad-ΔE1B in this paper), induced viral cytolysis as well as E1A-mediated apoptosis, 
leading to an improved efficacy over E1B 55kDa-deleted replication-competent 
adenovirus, Ad-ΔElB55 8.  
Overall, selective replication and viral spread within cancer cells has seen some 
success, but the overwhelming promise that was once projected has not been fully 
realized mainly due to the uneven penetration and viral distribution of these engineered 
Ads within tumor tissues. To date, ONYX-015 (originally named dl1520), an E1B 55kD 
gene-deleted oncolytic adenovirus, has been tested in over 15 clinical trials in a range of 
tumor types 9,10, but only has reported limited success (7 to 14% local response rate) in 
patients with head and neck cancer, and worse no single agent efficacy was noted in 
other tumor types 11. In preclinical xenograft tumor model studies, wild-type adenovirus 
has been shown to delay the growth of tumors, but rarely is able to eradicate established 
tumors. Recently, Sauthoff et al. demonstrated that high level of titratable Ads persisted 
within xenograft tumors for at least 8 weeks after intratumoral injection of the wild-type 
adenovirus 12, but the pattern of viral distribution within the tumor tissue was uneven 
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and patchy. The long-term viral persistence without complete responses suggests that 
viral spread maybe limited and that this limitation could be an important mechanism for 
the reported lack of efficacy. 
Recent evidence has shown that connective tissue and extracellular matrix 
(ECM) may play a prominent role in inhibiting viral spread following their 
administration. First, Kuriyama et al. demonstrated that treatment with 
collagenase/dispase or trypsin prior to intratumoral injection of adenovirus, enhanced 
virus-mediated gene transduction 13. Similarly, Maillard et al. elevated the efficiency of 
adenovirus-mediated gene transfer by about two-fold by treating rabbit iliac arteries 
with elastinase, an enzyme which dissociates elastin 14. More recently, studies from our 
laboratory have demonstrated that ECM degradation by relaxin expressed from 
adenovirus increased viral spread throughout the tumor mass, resulting in an 
enhancement of transduction efficiency in solid tumors in vitro and in vivo 15. Relaxin 
also demonstrated superior viral distribution of replicating oncolytic adenovirus, leading 
to an increased anti-tumor effect and survival advantage. 
To extend our understanding of the role of the ECM barrier and connective 
tissue in inhibiting viral spread and penetration within tumor masses, we evaluated the 
utility of decorin. Decorin, a small leucine-rich proteoglycan, is a ubiquitous component 
of the ECM and is preferentially found in association with collagen fibrils 16. Decorin 
binds to collagen fibrils and delays the lateral assembly of individual triple helical 
collagen molecules, resulting in the decreased diameter of the fibrils. Decorin may also 
affect the production of other ECM components by blocking the activity of transforming 
growth factor-β (TGF-β) 17. Additionally, decorin can modulate the interactions of ECM 
components such as fibronectin and thrombospondin with cells. Furthermore, decorin is 
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capable of affecting the ECM remodeling via induction of the matrix metalloproteinase 
collagenase (MMP-1) 16,18. These observations suggest that decorin regulates the 
production and assembly of the ECM at several levels and hence play a prominent role 
in remodeling connective tissues.  
Given the importance of decorin’s role in the ECM remodeling, we 
hypothesized that an increased expression of decorin would facilitate the spread of Ads 
within tumor tissues. We show here that expression of decorin dramatically increased 
the transgene expression and functionally, the dispersion of Ads within tumor tissues. As 
such the oncolytic potency of a decorin-expressing replicating adenovirus was 
significantly greater, both in vitro and in vivo. Taken together, these data demonstrate 
the utility of decorin as a dispersion agent, and suggest that decorin exhibits a high 
potential in improving the efficacy of replicating adenovirus-mediated cancer gene 
therapy.  
 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
48
5.
1 
: P
os
te
d 
3 
Ja
n 
20
08
Kim et al. 
 6
Results 
 
Construction of decorin-expressing adenoviruses and expression pattern of decorin 
To evaluate role of decorin in altering tumor penetration efficiency, replication-
incompetent dl-LacZ-DCNG, dl-LacZ-DCNQ, and dl-LacZ-DCNK adenoviruses 
expressing LacZ as a reporter were constructed. Tumor-specific replication-competent 
adenoviruses (Ad-ΔE1B-DCNG, Ad-ΔE1B-DCNQ, and Ad-ΔE1B-DCNK) were also 
constructed to enhance viral spreading into tissues. Point mutants of decorin gene, 
DCNK and DCNQ, contain substituted nucleotides at the region which plays a pivotal 
role in binding to type I collagen fibril. The first mutant, DCNQ, harbors a point 
mutation at the E180 amino acid site (E180Q), which is located in the sixth leucine-rich 
repeat of the wild type decorin core protein, and has a moderate binding affinity to type 
I collagen fibril. The second mutant, DCNK, also harbors an amino acid exchange at the 
amino acid E180 site but is substituted with lysine (K), resulting in lack of binding 
affinity to type I collagen fibril 19,20. To assess the activity of the adenoviruses, U343 
cells were infected with replication-incompetent dl-LacZ-DCNG, dl-LacZ-DCNQ, and 
dl-LacZ-DCNK adenoviruses at 20 MOI or tumor-specific oncolytic adenoviruses Ad-
ΔE1B, Ad-ΔE1B-DCNG, Ad-ΔE1B-DCNQ, and Ad-ΔE1B-DCNK at 5 MOI, and 
medium was then recovered for Western blotting. Cells infected with dl-LacZ or Ad-
ΔE1B as negative controls for replication-incompetent adenovirus and tumor-specific 
oncolytic adenovirus were revealed not to express decorin, whereas all those infected 
with dl-LacZ-DCNG, dl-LacZ-DCNQ, dl-LacZ-DCNK, Ad-ΔE1B-DCNG, Ad-ΔE1B-
DCNQ, and Ad-ΔE1B-DCNK showed decorin expression (Fig. 1).  
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Evaluation on spreading and penetration potency of decorin-expressing adenoviruses to 
tumor tissue 
In order to evaluate the penetration potency of decorin-expressing adenoviruses, 
U343 and U87MG tumor xenografts grown in nude mice were intratumorally injected 
with dl-LacZ or dl-LacZ-DCNG at 5 x 108 PFU for three injections. At 3 days post final 
adenoviral injection, tumor tissue was removed and stained for expression of β-
galactosidase (Fig. 2A). While dl-LacZ exhibited low level of LacZ expression and the 
staining region was localized to the viral injection site, dl-LacZ-DCNG showed much 
higher LacZ expression and the stained region was found to be widely distributed other 
regions of the tumor. In comparison, both dl-LacZ-DCNK and dl-LacZ-DCNQ showed 
much lower LacZ expression was present in limited areas of the tumor. These results 
clearly demonstrate that tissue penetration potency of dl-LacZ-DCNG is greatly 
enhanced than those of dl-LacZ, dl-LacZ-DCNQ, and dl-LacZ-DCNK, and this 
enhanced tissue penetration effect derived from decorin-expressing adenovirus is 
dependent on the binding affinity of decorin to collagen fibril.  
To further confirm the enhanced transduction efficiency and tissue penetration 
potency of wild-type decorin-expressing adenovirus, GFP-expressing adenoviruses (5 x 
108 PFU of dl-GFP or dl-GFP-DCNG) were injected 3 times every other day into U87 
tumor xenografts established in nude mice. Three days following the final injection, 
tumors were then harvested and photographed using a confocal microscope. As shown 
in Fig. 2B, we observed narrow path of fluorescence in the tumors infected with dl-GFP, 
which is assumed as a needle track formed when we injected viruses into tumors. In 
marked contrast, we observed fluorescence in more extended area of the tumor mass 
treated with dl-GFP-DCNG, and was not limited to sites of injections.  
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Furthermore, to examine whether the enhanced transduction efficiency and 
tissue penetration potency of decorin-expressing adenovirus can also be translated to 
primary human tumor tissues, tumor spheroids were prepared from human patients with 
brain or breast cancers.  The spheroids were transduced with LacZ- or GFP-expressing 
adenoviruses (1 x 107 PFU of dl-LacZ, dl-LacZ-DCNG, dl-GFP, or dl-GFP-DCNG). 
Three days after viral infection, the tumor spheroids were then observed under a light or 
fluorescence microscope. As shown in Fig. 3, LacZ or GFP expression was limited on 
the surface of primary tumor spheroids treated with either dl-LacZ or dl-GFP.  In 
contrast, LacZ or GFP was strongly and widely expressed in most of tissues of the 
glioma and breast primary tumor spheroids treated with either dl-LacZ-DCNG or dl-
GFP-DCNG. This profile of transduction efficiency and viral spread confirmed the 
observations noted from the in vivo experiments using human xenograft models.  
 
Assessment decorin-expressing oncolytic adenovirus’ ability to kill tumor cells   
To link that the increase in spreading of decorin-expressing adenovirus 
contributes to enhanced tumor cell killing, an in vitro cytopathic effect assay was 
carried out. Two human glioma cell lines (U343 & U87MG) and human normal cell 
lines (CBHEL, IMR90, and WI38) were infected with dl-LacZ, Ad-ΔE1B, Ad-ΔE1B-
DCNG, Ad-ΔE1B-DCNQ, or Ad-ΔE1B-DCNK adenovirus at MOIs of 0.1- 20 for 
glioma cell lines and 0.1-100 for normal cell lines, and the tumor cell killing effect was 
analyzed. As shown in Fig. 4, as expected, dl-LacZ had no effect in killing glioma cell 
lines.  In contrast, Ad-ΔE1B-DCNG exhibited about 10-20 fold higher tumoricidal 
effect than Ad-ΔE1B control oncolytic adenovirus. This result was consistent over 
several independent experiments, indicating that decorin expression does not decrease 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
08
.1
48
5.
1 
: P
os
te
d 
3 
Ja
n 
20
08
Kim et al. 
 9
the replication competency of adenoviruses and contributes to the dramatic increase in 
tumoricidal effect of adenoviruses as well. Interestingly, the tumoricidal effects of Ad-
ΔE1B-DCNQ and Ad-ΔE1B-DCNK were decreased upon lowering the binding affinity 
to collagen compared to that of Ad-ΔE1B-DCNG. In marked contrast, Ad-ΔE1B-
DCNG in normal cells showed no significant changes in cell killing effect compared to 
Ad-ΔE1B, highlighting the cancer specificity of this Ad.  
 
Evaluation on anti-tumor efficacy of decorin-expressing oncolytic adenovirus in vivo 
Wild-type decorin-expressing oncolytic adenovirus, Ad-ΔE1B-DCNG, was 
next examined for its ability to suppress the growth of human tumor xenografts, U343 
and U87MG glioma models established in nude mice. Tumors were generated by 
subcutaneous injection of cells into the mice abdominal region. When tumors reached 
an average size of 70-100 mm3, 5 x 108 PFU of viral load were injected intratumorally 3 
times, every other day. As shown in Fig. 5A, the growth of oncolytic adenovirus-treated 
tumors was substantially delayed in all human xenograft models examined. For U343 
xenograft model, the control mice treated with PBS resulted in the considerable tumor 
growth to 2118.17 ± 144.96 mm3 at day 53 post-treatment, whereas Ad-ΔE1B and Ad-
ΔE1B-DCNG led to the significant suppression of tumor growth to 916.00 ± 191.78 
mm3 and 329.80 ± 126.74 mm3, showing 57% (P < 0.001 versus PBS) and 84% (P < 
0.001 versus PBS; P < 0.05 versus Ad-ΔE1B) tumor growth inhibition, respectively. 
Similarly, Ad-ΔE1B-DCNG-treated U87MG glioma tumors also showed remarkable 
anti-tumor effect than those treated with Ad-ΔE1B, demonstrating that the decorin-
expressing oncolytic adenovirus has stronger anti-tumor potency than Ad-ΔE1B. At 34 
days after treatment for U87MG xenograft models, more specifically, Ad-ΔE1B and 
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Ad-ΔE1B-DCNG adenoviruses led to the tumor volume of 591.30 ± 180.44 and 38.33 ± 
36.03, respectively, showing a decrease of 94% (P < 0.05 versus Ad-ΔE1B) in tumor 
volume in Ad-ΔE1B-DCNG-treated mice relative to Ad-ΔE1B-treated mice. Moreover, 
Ad-ΔE1B-DCNG adenovirus completely eradicated tumors in 5 out of 7 mice. 
 
Figure 5B shows survival curve for PBS-, Ad-ΔE1B-, and Ad-ΔE1B-DCNG-
treated tumor bearing mice. For U343 tumor bearing mice, 53 days after the beginning 
of the treatment, 100% of the animals treated with Ad-ΔE1B-DCNG were still viable, 
whereas 75% of Ad-ΔE1B-treated mice were viable in the same time period. Similarly, 
Ad-ΔE1B-DCNG-induced survival benefits were obtained in U87MG xenograft models. 
Throughout the course of the study, no systemic toxicity, such as diarrhea, loss of 
weight, or cachexia was observed. These results demonstrate that Ad-ΔE1B-DCNG can 
confer significant survival advantage and tumor reduction in vivo.  
 
Change of tumor characteristics induced by decorin-expressing oncolytic adenovirus 
The enhanced anti-tumor effect of decorin-expressing oncolytic adenovirus was 
further investigated by histological examination. Tumors were harvested from each 
treatment group at 3 days after the three sequential treatments. Hematoxylin and eosin 
(H & E) staining revealed that the majority of remaining tumor mass treated with Ad-
ΔE1B-DCNG was necrotic, whereas necrotic lesions were only detectable in the limited 
region of tumors treated with Ad-ΔE1B (Fig. 6A). Viral distribution within the tumor 
mass was then confirmed by immunohistochemistry using an antibody specific to 
adenoviral hexon protein. Marked increase in number of adenoviral particles was 
detected in wider areas of Ad-ΔE1B-DCNG-treated U343 and U87MG tumors in 
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comparison to Ad-ΔE1B-treated tumors. To analyze the degree to which Ad-ΔE1B-
DCNG induced apoptosis in vivo, TUNEL assay was carried out. As seen in Fig. 6A, 
apoptotic level was significantly higher in Ad-ΔE1B-DCNG-treated tumor tissue than in 
PBS- or Ad-ΔE1B-treated tumor tissue, thus demonstrating that Ad-ΔE1B-DCNG 
adenovirus replicates actively in the viral injection site and spreads widely, contributing 
to the induction of apoptosis and necrosis. 
 
Change of ECM components in tumor mass treated with decorin-expressing adenovirus 
Tumor section slides from the tumor-bearing nude mice treated with Ad-ΔE1B 
or Ad-ΔE1B-DCNG were first stained using biebrich’s scarlet acid fuchsin (Masson’s 
trichrome stain) to analyze the distribution of collagen fibers (stained blue color), a 
major component of extracelluar matrix. As shown in Fig. 6B, U343 tumors treated with 
Ad-ΔE1B consisted of high content of collagen fibers (blue staining). In marked 
contrast, tumors treated with Ad-ΔE1B-DCNG appeared to be devoid of collagen fibers, 
indicating that decorin expression dramatically reduced the content of collagen fibers 
within the tumor mass. We further stained the tumor tissues with antibodies specific to 
collagen type I, collagen type III, and elastin. All these ECM components were 
prominent in the PBS- and Ad-ΔE1B-treated control tumor tissues, whereas almost no 
immunopositivity was observed in Ad-ΔE1B-DCNG-treated tumors, mirroring the 
findings with the Massons’s trichrome staining. These results closely parallel and 
support the increased viral spread in the tumor mass and enhanced anti-tumor effect of 
decorin-expressing oncolytic adenovirus. 
 
Inhibition of tumor metastasis by decorin-expressing oncolytic adenovirus 
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Since degradation of extracellular matrix has the potential to increase tumor 
metastasis, the impact of decorin expression on metastatic potential was examined using 
a spontaneous metastasis model. B16BL6 melanoma cells (1.5 x 105/mouse) were 
implanted subcutaneously to form a local primary tumor on the right hind footpad of 
C57BL/6 mice, and metastases to distant organs were measured after the removal of the 
primary tumor. As shown in Fig. 7, B16BL6 metastatic tumor nodules in the lung were 
considerably reduced by treatment with Ad-ΔE1B or Ad-ΔE1B-DCNG. The average 
number of metastasized nodules in the lung from mice treated with Ad-ΔE1B and Ad-
ΔE1B-DCNG was 8.3 ± 2.4 and 2.3 ± 0.9 compared to PBS-treated control group (41 ± 
8.2), translating to 80% (P < 0.01) and 94% (P < 0.01) inhibition, respectively. 
Moreover, treatment with Ad-ΔE1B-DCNG further decreased pulmonary metastasis 
relative to Ad-ΔE1B, showing 72% inhibition (P < 0.05). These data indicate that the 
intratumoral injection of oncolytic adenovirus expressing decorin in primary tumor site 
greatly reduced and not enhanced the formation of metastatic lesions at distal sites 
compared to its cognate control oncolytic adenovirus in this model system. 
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Discussion 
 
An important issue that has received little attention, but is fundamentally 
critical in improving viral-based cancer gene therapy, is the limited distribution of 
viruses within solid tumor tissues. Recent evidence has shown that connective tissue 
and ECM may play a prominent role in inhibiting viral spread. Harrison et al. showed 
that even though viable replicating viruses persisted within the bulk of the tumor, the 
connective tissue within established tumors hindered its spread and thus blocked 
complete tumor eradication 6. Similarly, it has been shown that viral spreading is 
impaired by the presence of tumor-supporting structures 12.  Moreover, in a phase I 
clinical trial for recurrent glioma, it has been demonstrated that the zone of transduced 
cells did not extend beyond 5 mm from the site of injection 21. To infect cells that are 
distally located from the site of viral inoculation, replicating adenovirus must transverse 
the extracellular space between cells and connective tissue. Therefore, strategies aimed 
at increasing the extent of anatomic distribution of replicating virus within a tumor mass 
would be desirable and timely. 
To address this issue, we explored the use of decorin to enhance viral spreading 
and tumor tissue penetration. The enhanced gene transfer efficiency and viral spreading 
of dl-LacZ-DCNG was evident in solid tumor mass in vivo, where intratumoral injection 
with dl-LacZ-DCNG resulted in much more extensive LacZ staining throughout the 
entire tumor tissue than that with dl-LacZ. Further, mutant decorin-expressing 
adenoviruses, dl-LacZ-DCNQ and dl-LacZ-DCNK, lost their ability to enhance gene 
transfer efficiency and tissue penetration in tumor tissues. In accordance with these 
results, GFP-expressing dl-GFP-DCNG also increased viral spreading and tumor tissue 
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penetration in U87MG xenograft models as well as human primary tumor tissues, 
confirming the decorin-mediated increase in transduction efficiency. Taken together, 
these lines of evidence demonstrate that decorin expression significantly enhanced the 
transgene expression carried by adenoviral vectors and facilitated the viral dispersion 
throughout the tumor tissue both in vitro and in vivo.  
The role of decorin in markedly enhancing the transduction efficiency of 
decorin-expressing adenoviruses (dl-LacZ-DCNG & dl-GFP-DCNG) is likely due to its 
role in degrading the ECM of tumors/spheroids. We observed that the gene transfer 
efficiency of dl-LacZ-DCNG in comparison to dl-LacZ was more intensified when 
these engineered adenoviruses were injected multiple times (Data not shown). Since 
tumor spheroids were cultured for 3 days in the culture medium, residual adenovirus 
can infect cells continuously into the core of the spheroid. Similarly in vivo, established 
xenografts were treated repeatedly, allowing ample time for decorin to reduce the ECM 
content of the tumor tissue by the initial exposure and subsequent penetration and 
spread of Ads by the repeated treatment. In both cases, previous exposure to dl-LacZ-
DCNG seems to make the tumor environment much more favorable to subsequent viral 
infections. 
Utilization of decorin also successfully enhanced viral spread of replicating 
adenovirus, leading to an increased anti-tumor effect. In CPE assay, Ad-ΔE1B-DCNG 
showed increased cell killing potency compared to Ad-ΔE1B. Of note, the cell killing 
effect of Ad-ΔE1B-DCNQ and Ad-ΔE1B-DCNK was decreased as the binding affinity 
to collagen was decreased, demonstrating that the increase of cell killing effect is driven 
by decorin’s action on extracellular matrix. The enhanced cell killing potency of 
decorin-expressing adenovirus also translated into in vivo, as greater anti-tumor and 
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survival advantage was observed for Ad-ΔE1B-DCNG treated tumor bearing mice. In 
particular, the anti-tumor activity of Ad-ΔE1B-DCNG in the U87MG xenograft models 
was striking, as 5 out of 7 mice underwent complete regressions. Viral persistence and 
distribution within tumor tissues were confirmed by immunohistohemistry, where a 
marked increase in number of adenoviral particles in Ad-ΔE1B-DCNG-treated tumor 
was detected as compared to control. Ad-ΔE1B-DCNG also substantially decreased 
ECM components within tumor tissues, while normal tissue adjacent to the tumor cells 
was not affected. These findings provide further support for the ECM’s role in inhibiting 
the viral spread what we have previously demonstrated with relaxin 15.   
Decorin has a high affinity binding site for TGF-β, so that binding of decorin to 
TGF-β neutralize its biological activity 17. TGF-β is a pro-fibrotic cytokine that induces 
the accumulation of ECM via the inhibition of proteolytic enzymes and the 
enhancement of their tissue inhibitors. We found that TGF-β protein levels were 
reduced by decorin-expressing adenoviruses (dl-LacZ-DCNG & Ad-ΔE1B-DCNG) not 
only in U343 glioma cells but also in tumor tissues, supporting the notion that decorin is 
a natural inhibitor of TGF-β (Supplement Data. 1 & 2). In addition, the proteoglycan 
decorin is known to bind collagen fibrils near the d bands and delays the lateral 
assembly of collagen fibrils 16. In accordance with these results, we observed that the 
level of collagen fibrils was significantly decreased in the tumor tissues treated with 
decorin-expressing adenovirus.  
Finally, intratumoral administration of Ad-ΔE1B-DCNG did not enhance but 
inhibited the formation of pulmonary metastases of B16BL6 melanoma cells in mice. 
Treatment with Ad-ΔE1B-DCNG resulted in a 94% inhibition (P < 0.01) of pulmonary 
metastases versus 80% (P < 0.01) for Ad-ΔE1B relative to PBS treatment, suggesting 
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that decorin-expressing oncolytic adenovirus can elicit potent anti-tumor efficacy not 
only against solid tumor but also against metastatic tumor lesions. Moreover, the 
therapeutic advantage of treatment with decorin-expressing oncolytic adenovirus 
demonstrated in this study using a murine spontaneous metastatic model would be 
greatly enhanced in a human system because human tumor cells are much more 
permissive to adenoviral infection and replication. 
The pressing challenge for contemporary gene therapy is to deliver enough 
therapeutic genes to enough cancer cells in vivo. The application of decorin to enhance 
the ability of adenovirus to facilitate cell-to-cell dispersion resulted in significantly 
enhanced anti-tumor effect of replicating adenovirus in a variety of tumor xenograft 
models. This study is the first to report utilization of decorin to achieve therapeutic 
benefit with increased distribution of viral vectors in tumor tissues. In addition, we also 
demonstrate the usefulness of replication-incompetent adenovirus-mediated transfer of 
decorin as well as that of oncolytic adenovirus-mediated transfer of decorin. In 
summary, our findings presented here indicate that the expression of decorin may be a 
useful strategy in enhancing the efficacy of virus-mediated cancer gene therapy.  
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Materials and Methods 
 
Cell lines and cell culture  
U343 and U87MG human glioma cell lines and HEK293 (human embryonic 
kidney cell line expressing the adenoviral E1 region) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco BRL) supplemented with 10% fetal bovine 
serum (Gibco BRL), L-glutamine (2 mM), penicillin (100 IU/ml), and streptomycin (50 
μg/ml). The murine B16BL6 melanoma cells 15 were grown in MEM supplemented 
with 5% FBS, vitamin solution (1 mM), sodium pyruvate (100 mM), nonessential 
amino acid (10 mM), penicillin (500 IU/ml), and streptomycin (50 μg/ml). All cell lines 
were maintained 37oC in a humidified atmosphere at 5% CO2. 
 
Experimental animals 
 In vivo anti-tumor experiments were conducted using 6- to 8-week-old male 
nude mice (BALB/c-nu) and C57BL/6 mice purchased from Charles River Korea 
(Seoul, Korea). All mice were maintained in a laminar air-flow cabinet under specific 
pathogen-free conditions. All facilities are approved by AAALAC (association of 
assessment and accreditation of laboratory animal care), and all animal experiments 
were conducted under the institutional guidelines established for the Animal Core 
Facility at Yonsei University College of Medicine. 
 
Generation of decorin-expressing adenoviruses 
To generate adenoviruses expressing decorin at the E3 region, wild-type and 
mutant decorin genes were first excised from pcDNA3.1-DCNG (containing the wild-
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type decorin cDNA), pcDNA3.1-DCNQ (containing mutant-type decorin cDNA having 
weaker binding affinity to collagen), and pcDNA3.1-DCNK (containing mutant-type 
decorin cDNA lacking binding affinity to collagen) 19,20 using EcoRI-XbaI and resulting 
1 kb DNA fragments were subcloned into the pCA14 vector (Microbix, Ontario, 
Canada), generating pCA14-DCNG, pCA14-DCNQ, and pCA14-DCNK vector, 
respectively. The mutant decorin DCNQ harbors a point mutation of E180 amino acid to 
E180Q in the sixth leucine-rich repeat of the wild type decorin core protein. The mutant 
decorin DCNK harbors an amino acid exchange at amino acid E180, which is an 
important site for the interaction of decorin with type I collagen fibrils. Each of the 
pCA14-DCNG, pCA14-DCNQ, and pCA14-DCNK vectors were digested with BamHI, 
and the CMV-decorin-polA expression cassettes were then subsequently cloned into the 
adenoviral E3 shuttle vector pSP72-E3 22 resulting in pSP72-E3/CMV-DCNG, pSP72-
E3/CMV-DCNQ, pSP72-E3/CMV-DCNK adenoviral E3 shuttle vectors. The adenoviral 
E3 shuttle vectors thus prepared were linearized with XmnI and cotransformed into E. 
coli BJ5183 together with the adenoviral total vector, pdl-LacZ linearized with SpeI for 
homologous recombination, generating the replication-incompetent adenoviral vectors 
dl-LacZ-DCNG, dl-LacZ-DCNQ, and dl-LacZ-DCNK which express the LacZ and 
decorin simultaneously. We also generated tumor-specific oncolytic adenoviruses 
expressing the decorin gene. Specifically, each of dl-LacZ-DCNG, dl-LacZ-DCNQ, and 
dl-LacZ-DCNK was linearized with XmnI and cotransformed into E. coli BJ5183 
together with the E1B19 kDa/E1B55 kDa-deleted pAdΔE1B19/55 adenovirus vector 
linearized with SpeI 23 for homologous recombination, generating the Ad-ΔE1B-DCNG, 
Ad-ΔE1B-DCNQ, and Ad-ΔE1B-DCNK adenovirus vectors, respectively. To verify the 
occurrence of homologous recombinants, the recombinant adenoviral vectors were 
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digested with HindIII, and the digestion pattern was analyzed. The proper homologous 
recombinant adenoviral vectors were digested with PacI and transfected into 293 cells 
to generate adenoviruses. All adenoviruses were propagated in 293 cells and their 
titration was performed according to limited dilution assay, followed by concentration 
using CsCl gradient and purification. Viral particle (v.p.) numbers were also calculated 
from measurements of optical density at 260 nm (OD260), where 1 absorbency unit is 
equivalent to 1012 viral particles per milliliter.  
 
Examination of decorin expression 
To examine the decorin expression pattern induced by generated recombinant 
adenoviruses, replication-incompetent adenoviruses and oncolytic adenoviruses 
harboring the decorin gene (dl-LacZ-DCNG, dl-LacZ-DCNQ, dl-LacZ-DCNK, Ad-
ΔE1B-DCNG, Ad-ΔE1B-DCNQ, and Ad-ΔE1B-DCNK) and dl-LacZ and Ad-ΔE1B 
adenovirus as negative controls were infected to U343 at 20 MOI for replication-
incompetent adenoviruses and at 5 MOI for oncolytic adenoviruses. At 48 hr after 
infection, the medium used was recovered and subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Then, the proteins on the gel were 
electro-transferred to PVDF membrane, incubated with the primary anti-decorin 
antibody (AF143; R & D Systems, Minneapolis, MN) and anti-β-actin antibody (Sigma, 
St. Louis, MO), and then incubated with the HRP (horse radish peroxidase)-conjugated 
secondary antibody (6160-05; Southern Bio Technology Associates, Inc. Birmingham, 
AL), after which the expression patterns of decorin were revealed using the ECL 
detection kit (sc-2004; Santa Cruz Biotechnology, Santa Cruz, CA). 
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Evaluation on spreading and penetration of adenoviruses in vivo  
To determine the extent of viral spreading and tumor penetration in vivo, U343 
and U87MG human glioma xenografts were established subcutaneously by injecting 
cells into the abdomen of 6- to 8-week-old male nude mice. Once the tumors reached to 
100-200 mm3 in volume, mice were randomized and dl-LacZ, dl-LacZ-DCNG, dl-
LacZ-DCNQ, or dl-LacZ-DCNK adenovirus at 5 x 108 PFU in 50 μl was intratumorally 
injected into the tumors three times, every other day. On day 3 after the last injection, 
animals were sacrificed and tumors were taken, after which they were fixed in 4% 
paraformaldehyde (PFA) at 4 for 4-8 hr and dehydrated in 30% sucrose solution for 12 
hr. The dehydrated tumor tissues were embedded in O.C.T. compound and snap frozen. 
Observance of blue staining with a light microscopy under low power was considered 
positive for β-galactosidase expression. Each experiment was carried out three to four 
times, and data from a representative experiment are shown. 
 
Evaluation on transduction efficiency and tissue penetration potency of decorin-
expressing adenoviruses using tumor tissues from breast cancer and glioma patient 
Tumor tissues from breast cancer and glioma patients were freshly collected, 
cut into 1-2 mm sections and then plated onto HydroCell 12 Multi-well plates (CellSeed, 
Japan) after which they were cultured for 4 hr in IMDM (Isocove's Modified Dulbecco's 
Medium, Gibco BRL) supplemented with 5% FBS, 10 μM/L insulin and 1 μM/L 
hydrocortisone. Each of adenoviruses (dl-GFP or dl-GFP-DCNG for breast cancer 
spheroids and dl-LacZ or dl-LacZ-DCNG for glioma spheroids) at 1 x 107 PFU (breast 
cancer spheroids) or 1 x 108 PFU (glioma spheroids) were added into the plates 
containing primary tumor tissues, and incubated at 37 in 5% CO2 incubator for 11 
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(breast cancer spheroids) and 3 (glioma spheroids) days. For the observation on 
penetration of adenovirus into tumor spheroid, the X-gal stained tumor spheroids were 
embedded in O.C.T. compound (Sakura Finetec) and snap frozen, followed by 
performing X-gal staining described above. The glioma spheroids were observed under 
a fluorescence microscope. 
 
Anti-tumor effects and survival rates of decorin-expressing oncolytic adenovirus in vivo 
  Tumors were implanted on the abdomens of 5 to 6 week-old male nude mice by 
subcutaneous injection of 1 x 107 U343 and U87MG glioma cells in 100 μl of Hank’s 
balanced salt solution (HBSS; Gibco BRL). When tumors reached a range of 70~100 
mm3, animals were randomly assigned to one of three groups to receive PBS, Ad-ΔE1B, 
or Ad-ΔE1B-DCNG (seven or eight mice per group). The first day of treatment was 
designated as day 0. Adenovirus or PBS was administered intratumorally (5 x 108 PFU 
in 50 μl of PBS) on days 0, 2, and 4. Tumor growth delay was assessed by talking 
measurements every 2 or 3 days. The volume of tumors was calculated with the major 
axis and minor axis measured using a caliper: tumor volume = (minor axis mm)2 x 
(major axis mm) x 0.523. The percentage of surviving mice was determined by 
monitoring the death of mice (for U87MG xenografts) or tumor growth related events 
(tumor size > 1500 mm3 for U343 xenografts)  
 
Change of metastatic potential over decorin expression using spontaneous metastasis 
model 
To assess changes of metastatic potential over decorin expression, B16BL6 cells 
(1.5 x 105/mouse) were administered subcutaneously into the right hind foot pad of 6 
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week-old male C57BL/6 mice (Charles River Korea, Seoul, Korea) to form primary 
tumors. When the primary tumor reached a volume of about 200 mm3, animals were 
randomly assigned to one of three groups to receive PBS, Ad-ΔE1B, or Ad-ΔE1B-
DCNG (six to eight mice per group). The first day of treatment was designated as day 0, 
and then 5 x 108 PFU per tumor in 50 ㎕ of PBS, mixed with Lipofectamine and Plus 
solution (Gibco BRL) at a 2 : 6 ratio or PBS was injected directly into the tumor on 
days 0, 2, and 4. On day 7, primary tumors were surgically removed by amputating the 
right hind leg below the knee under mild anesthesia. On day 28 after primary tumor 
lesions in the lungs of the mice was assessed.   
 
Observation of the change of tumor characteristics induced by the administration of 
decorin-expressing adenovirus 
Tumor tissue was fixed in 10% formalin, embedded in paraffin and cut into 3-
μm sections (Wax-it; Vancouver, Canada). Representative sections were stained with 
hematoxylin-eosin or with Masson’s trichrome and then examined by light microscopy. 
We used reagents supplied by DAKO ARK (Dako, Carpinteria, CA) to detect 
adenoviral antigens, as described previously 24. The same paraffin slides were also used 
to identify apoptotic cells in tumors according to the instructions in the ApopTag kit for 
detecting cleaved deoxyribonucleic acids in situ with the TUNEL method. For the 
detection of collagen type I, collagen type III, and elastin in tumor tissues, paraffin 
tumor sections were first treated with monoclonal anti-collagen type I antibody (sc-
25974; Santa cruz biotechnology),  monoclonal anti-collagen type III antibody (C7805; 
Sigma, St. Louis, MO), or monoclonal anti-elatin antibody (E4013; Sigma), and then 
with goat anti-mouse IgG-Biotin (sc-2039; Santa Cruz Biotechnology) as a secondary 
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antibody. Finally, diaminobenzidine/hydrogen peroxidase (Dako) was used as the 
chromogen substrate. All slides were counterstained with Meyer’s hematoxylin. 
 
Statistical Analysis 
The data were expressed as mean ± standard error of the mean (SEM). 
Statistical comparison was made using Stat View software (Abacus Concepts, Inc., 
Berkeley, CA) and the Mann-Whitney test (nonparametric rank sum test). The criterion 
for statistical significance was taken as P < 0.05. 
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Figure Legends 
Fig. 1. Representative Western blot analysis of human decorin from medium collected 
at day 2 after infection. The results showed a significant expression of the virally-
transduced decorin gene.  
 
Fig. 2. Enhanced transduction efficiency and viral spreading of decorin-expressing 
adenoviruses. (A) U343 and U87MG xenografts were established in nude mice, and 
then intratumorally injected with dl-LacZ , dl-LacZ-DCNG, dl-LacZ-DCNQ, or dl-
LacZ-DCNK adenovirus (5 x 108 PFU) three times every other day. At 3 days after the 
last injection of adenovirus, tumors were harvested and processed for LacZ staining. 
Original magnification: x 40 and x 400. (B) The U87MG xenografts established in nude 
mice was injected three times with dl-GFP or dl-GFP-DCNG (each at 5 x 108 PFU). 
Three days after the last injection of adenoviruses, tumors were harvested and 
photographed with a confocal microscope. In the tumors treated with dl-GFP, we 
observed a narrow path of fluorescence that appeared to follow the needle track when 
we injected the viruses. In contract, in the tumors treated with dl-GFP-DCNG, 
fluorescence was distributed through the tumor mass. Original magnification: x 100. 
Fig. 3. Tumor spheroids prepared from a human patient with glioma (A) and breast 
cancer (B). Spheroids were transduced with either dl-LacZ or dl-LacZ-DCNG for 
glioma spheroids (1 x 108 PFU) and either dl-GFP or dl-GFP-DCNG for breast cancer 
spheroids (1 x 107 PFU). The glioma spheroids were photographed with a light 
microscope for LacZ expression at 3 days post-infection and breast cancer spheroids 
were photographed with a fluorescence microscope for GFP expression at 11 days post-
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infection. Increased gene transfer, as shown by green fluorescence or LacZ staining, 
was achieved with decorin-expressing adenoviruses than with the control adenoviruses. 
Original magnification: x 40. 
 
Fig. 4. Enhanced cytopathic effect of decorin expressing oncolytic adenovirus. Cells 
were infected with dl-LacZ, Ad-ΔE1B, Ad-ΔE1B-DCNG, Ad-ΔE1B-DCNQ, or Ad-
ΔE1B-DCNK at the indicated MOI. At 4-8 days post-infection, surviving cells were 
stained using crystal violet. Replication-incompetent adenovirus dl-LacZ served as a 
negative control. Each cell line was tested at least three times, and data shown are from 
representative experiments.  
 
Fig. 5. Enhanced suppression of the growth of established tumors (A) and survival (B) 
following intratumoral injection with Ad-ΔE1B-DCNG compared to Ad-ΔE1B 
oncolytic adenovirus. Human glioma tumors were grown subcutaneously in the 
abdomen of nude mice and were subsequently injected directly with PBS (◆ ), Ad-
ΔE1B (◇ ), or Ad-ΔE1B-DCNG (○ ). Tumor volume was monitored regularly following 
treatment. The arrow indicates when treatment was given (5 x 108 PFU). Values 
represent the mean ± SEM (n=8 animals per group for U343; n=7 animals per group for 
U87MG). There was a statistically significant enhanced anti-tumor effects and longer 
survival in Ad-ΔE1B-DCNG-treated mice compared to Ad-ΔE1B treatment (P< 0.05). 
Fig. 6. Representative photomicrographs of U343 and U87MG tumor tissues 
demonstrating histological changes in response to administration of PBS, Ad-ΔE1B, or 
Ad-ΔE1B-DCNG. (A) H & E-stained sections of PBS-, Ad-ΔE1B-, or Ad-ΔE1B-
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DCNG-treated tumor tissue (H & E). Immunohistochemical staining of adenoviral 
hexon protein to localize adenovirus in tumor tissue (Ad hexon). Adenovirus-infected 
cells stain brown. Induction of apoptosis in tumor tissue was examined by TUNEL 
assay (TUNEL). Original magnification: x400. (B) Masson’s trichrome staining of 
ECM (blue staining) present in the tumor tissue sections (M & T). Tumors treated with 
Ad-ΔE1B-DCNG were significantly smaller than those treated with PBS or Ad-ΔE1B. 
Note the extensive bundles of collagen fibrils that stained blue with Masson’s trichrome 
in the tumors treated with PBS or Ad-ΔE1B (arrow). Masson’s trichrome-stained 
section of tumor tissue from Ad-ΔE1B-DCNG-treated animal was devoid of 
parenchymal trichrome staining, but murine normal tissue adjacent to tumor tissue was 
stained for collagen (arrow). Original magnification:  x1, x40 and x400; A higher 
magnification (x400) of the boxed area in x40 magnification. Immunostaining for 
collagene type I, collagen type III, and elastin. The content of ECM components are 
also significantly reduced in Ad-ΔE1B-DCNG-treated tumor tissues. 
. 
Fig. 7. Therapeutic efficacy of Ad-ΔE1B-DCNG on spontaneous pulmonary metastasis. 
When the B16BL6 primary tumor reached a volume of about 200 mm3, PBS, Ad-ΔE1B, 
or Ad-ΔE1B-DCNG was administered intratumorally three times every other day. On 
day 7 after viral injection, the primary tumors were then surgically removed. On day 28 
after primary tumor removal, the number of metastasized nodules in the lungs of the 
each mouse was counted and plotted. Each point represents the tumor nodules for every 
individual mouse (6 mice for PBS group, 7 mice for Ad-ΔE1B, and 8 mice for Ad-
ΔE1B-DCNG) and the mean number of metastasized nodules for each group is shown 
with a line. *P < 0.01 vs. PBS-treated control and *P < 0.05 vs. Ad-ΔE1B-treated group.  
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Supplement Data Legends 
 
Supplement Data 1. Suppression of TGF-β expression in decorin-expressing 
adenovirus-treated glioma cells. U343 cells were transduced with either dl-LacZ or dl-
LacZ-DCNG at different MOIs, and TGF-β expression was measured in the culture 
medium by conventional ELISA kits. The results showed a significant suppression of 
the TGF-β expression upon transduction with decorin-expressing adenovirus, whose 
levels decreased in a dose-dependent manner.   
 
Supplement Data 2. Immunohistochemical analysis for TGF-β. Formalin-fixed tumor 
tissues were embedded in paraffin and sectioned. Paraffin tumor sections were stained 
with anti-TGF-β monoclonal antibody, MAB1032 (Chemicon). Representative 
histological features of U343 tumors at x400 magnification were documented. The level 
of TGF-β expression was significantly decreased in the tumor tissues treated with 
decorin-expressing oncolytic adenovirus, Ad-ΔE1B-DCNG.  
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